Oseltamivir (Tamiflu)

Prodrug Mechanism

Activation Pathway: Ethyl Ester → Active Carboxylate

  Oseltamivir phosphate (oral prodrug)
          │  Absorbed in GI tract (bioavailability ~80%)
          ▼
  Oseltamivir (free base ethyl ester) — in portal circulation
          │  CES1 (carboxylesterase 1) — liver microsomes
          │  Hydrolysis of ethyl ester bond
          ▼
  Oseltamivir carboxylate (ACTIVE FORM)
          │  Poor CNS penetration (polar, ionised at physiological pH)
          │  Renally eliminated (dose-adjust if eGFR <30 mL/min)
          │  Half-life: ~6–10 hours (active metabolite)
          ▼
  Neuraminidase active site — competitive inhibition
  (mimics transition state of sialic acid cleavage by NA)

Why a prodrug? Oseltamivir carboxylate is polar and poorly absorbed orally. The ethyl ester prodrug is lipophilic enough for GI absorption; CES1 in the liver efficiently cleaves the ester to release the active polar carboxylate into systemic circulation. This strategy achieves ~80% bioavailability for an otherwise poorly absorbed compound.

CES1 pharmacogenomics: CES1 activity varies with a common functional variant (G143E, rs71647871). Carriers of loss-of-function alleles (~4% of Caucasians) have substantially higher oseltamivir and lower active carboxylate concentrations — potentially reduced efficacy and increased prodrug-associated adverse effects (nausea). This variant is absent in East Asian populations.

Mechanism of Action — Neuraminidase Inhibition

Influenza NA Biology and Inhibition

  Influenza virion surface:
  ┌─────────────────────────────────────────────┐
  │  HA (haemagglutinin) — binds sialic acid    │
  │  NA (neuraminidase) — cleaves sialic acid   │
  └─────────────────────────────────────────────┘

  Viral life cycle — NA's critical role:
  1. Virus attaches to sialic acid residues on host cell surface (via HA)
  2. Virus enters cell, replicates
  3. New virions bud from host cell surface, still bearing HA
  4. HA on new virions binds sialic acid on host cell → VIRIONS TETHERED
  5. NA cleaves sialic acid → virions released → spread to new cells

  With oseltamivir carboxylate:
  4. New virions bud — still tethered (HA binds sialic acid)
  5. NA active site BLOCKED by oseltamivir → sialic acid NOT cleaved
  6. Virions remain attached to host cell surface → self-aggregate
  7. Viral spread to neighbouring cells is prevented or markedly reduced
  8. Result: ↓viral titres → shorter illness, ↓severity, ↓lower RTI risk

  Structural basis: oseltamivir carboxylate mimics the transition state
  of sialic acid hydrolysis → fits tightly in the conserved NA active site
  (Arg118, Arg292, Arg371, Glu119, Glu276, Asp151, Tyr406 — conserved)

1. Competitive NA inhibition: Oseltamivir carboxylate binds the active site with Ki ~1 nM (N1, N2 subtypes); the conserved catalytic residues ensure cross-subtype activity across influenza A (all NA subtypes) and influenza B
2. Virion tethering: Without NA activity, HA on nascent virions forms non-productive interactions with sialic acid on the same or adjacent cells; virions self-aggregate and cannot infect new cells
3. Reduced viral load: Clinical studies show ~2–3 log reduction in peak viral titres with treatment started within 48 hours — correlates with symptom duration reduction
4. Immune modulation (secondary effect): Lower viral burden reduces cytokine response — potentially protective against the immunopathological excess cytokine production ("cytokine storm") implicated in severe influenza

Dosing

Resistance — H274Y and the N1 Problem

The most clinically significant resistance mutation is H274Y (His274Tyr) in the N1 neuraminidase subtype (re-numbered as H275Y in N2-based numbering used by some databases — the same physical mutation). This substitution:

• Mechanism of resistance: His274 normally forms a hydrogen bond that repositions Glu276 to interact with oseltamivir's bulky pentyl ether group. H274Y substitution prevents this repositioning → oseltamivir carboxylate no longer fits the active site; IC₅₀ increases >1000-fold
• Differential susceptibility: Oseltamivir-resistant H274Y mutant remains Zanamivir-sensitive — zanamivir lacks the pentyl ether group and binds differently; not affected by the His274Tyr change. This is why zanamivir is the treatment of choice for confirmed oseltamivir-resistant H1N1
• 2007–2009 community spread: H274Y variant of seasonal H1N1 spread globally in 2007–2008, achieving near-fixation in some countries (Norway >95%) WITHOUT oseltamivir selection pressure — a disturbing demonstration that resistance-fit viruses can emerge and spread naturally
• Pandemic H1N1 (2009) sensitivity: The 2009 pandemic H1N1 strain was generally oseltamivir-sensitive; sporadic H274Y mutants emerged in immunocompromised patients on treatment (oseltamivir-selected)
• H5N1 avian influenza: Most H5N1 strains sensitive to oseltamivir; H274Y variants detected in patients treated with oseltamivir. Oseltamivir remains the cornerstone of H5N1 treatment despite concerns

Evidence Base — The Controversy

The Cochrane / BMJ Data Access Saga

Oseltamivir has one of the most contested evidence bases in clinical pharmacology. The Cochrane Collaboration's Jefferson et al. repeatedly updated their systematic review as unpublished data became available — ultimately revealing that the original published literature substantially overstated benefits. The key issue: Roche (manufacturer) had not published approximately 60% of the clinical trial data on which regulatory approval was partly based. After a 4-year campaign by the BMJ and Cochrane (culminating in 2013 regulatory access to full clinical study reports), the conclusions from the complete dataset were considerably more modest than the published literature suggested.

Adverse Effects

• Nausea and vomiting (most common, ~10–15%) — dose-dependent; taking with food halves the incidence. Likely related to both the prodrug and active metabolite. Generally mild and resolve within 1–2 days; rarely require discontinuation
• Headache, dizziness — reported in ~5–10%; usually mild and transient
• Neuropsychiatric events (rare, predominantly Japan) — self-injury, delirium, and abnormal behaviour predominantly reported in Japanese children and adolescents. Japan's PMDA issued a warning in 2007 and restricted use in adolescents 10–19 years. The causal relationship remains uncertain — influenza itself causes neuropsychiatric effects (febrile delirium, influenza encephalopathy), confounding causality assessment. FDA and EMA added precautionary labelling; monitoring is recommended in all age groups, but restriction is limited to Japan's adolescent warning
• Skin reactions (rare) — Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme have been reported rarely; discontinue if skin reactions occur

Connections

References

• Jefferson T, Jones MA, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. doi:10.1136/bmj.g2545 · PubMed 24811411
• Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729-37. doi:10.1016/S0140-6736(14)62449-1 · PubMed 25640089
• Moscona A. Oseltamivir resistance — disabling our influenza defenses. N Engl J Med. 2005;353(25):2633-6. doi:10.1056/NEJMp058291 · PubMed 16371626
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(12):1619-29.
• WHO. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. World Health Organization, 2010.